The Future of Biopharmaceutical R&D and Manufacturing: A Spotlight Talk with AbSci

AbSci developed the Protein Printing™ technology, which results in dramatic reductions in the cost of producing biologics, acceleration of drug discovery timelines, and enables the production of previously difficult or impossible-to-produce molecules. By returning biomanufacturing to its E. coli roots, AbSci aims to replace CHO and other mammalian expression platforms as the expression host of choice.